The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis.
Cancers (Basel)
; 15(4)2023 Feb 12.
Article
in En
| MEDLINE
| ID: mdl-36831518
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Aspects:
Patient_preference
Language:
En
Journal:
Cancers (Basel)
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: